Stone J - Search Results

1

Pharmacokinetics of laropiprant and glucuronide metabolite in patients with severe renal insufficiency.

Stroh M, Wenning L, Luo WL, Desai R, Bi S, Keshavarz S, Lazarus N, Lunde NM, Smith WB, Schwartz M, Stone J, Wagner J, Lai E, Dishy V. Stroh M, et al. Among authors: stone j. Am J Ther. 2009 Sep-Oct;16(5):379-84. doi: 10.1097/MJT.0b013e318197c59d. Am J Ther. 2009. PMID: 19433974

2

Single- and multiple-dose pharmacokinetics of caspofungin in healthy men.

Stone JA, Holland SD, Wickersham PJ, Sterrett A, Schwartz M, Bonfiglio C, Hesney M, Winchell GA, Deutsch PJ, Greenberg H, Hunt TL, Waldman SA. Stone JA, et al. Antimicrob Agents Chemother. 2002 Mar;46(3):739-45. doi: 10.1128/AAC.46.3.739-745.2002. Antimicrob Agents Chemother. 2002. PMID: 11850256 Free PMC article. Clinical Trial.

3

Potential for interactions between caspofungin and nelfinavir or rifampin.

Stone JA, Migoya EM, Hickey L, Winchell GA, Deutsch PJ, Ghosh K, Freeman A, Bi S, Desai R, Dilzer SC, Lasseter KC, Kraft WK, Greenberg H, Waldman SA. Stone JA, et al. Antimicrob Agents Chemother. 2004 Nov;48(11):4306-14. doi: 10.1128/AAC.48.11.4306-4314.2004. Antimicrob Agents Chemother. 2004. PMID: 15504857 Free PMC article. Clinical Trial.

4

Dose-proportionality of a final market image sitagliptin formulation, an oral dipeptidyl peptidase-4 inhibitor, in healthy volunteers.

Bergman A, Mistry GC, Luo WL, Liu Q, Stone J, Wang A, Zeng W, Chen L, Dilzer S, Lasseter K, Herman GA, Wagner JA, Krishna R. Bergman A, et al. Among authors: stone j. Biopharm Drug Dispos. 2007 Sep;28(6):307-13. doi: 10.1002/bdd.559. Biopharm Drug Dispos. 2007. PMID: 17571284 Clinical Trial.

5

Absolute bioavailability of sitagliptin, an oral dipeptidyl peptidase-4 inhibitor, in healthy volunteers.

Bergman A, Ebel D, Liu F, Stone J, Wang A, Zeng W, Chen L, Dilzer S, Lasseter K, Herman G, Wagner J, Krishna R. Bergman A, et al. Among authors: stone j. Biopharm Drug Dispos. 2007 Sep;28(6):315-22. doi: 10.1002/bdd.560. Biopharm Drug Dispos. 2007. PMID: 17575559 Clinical Trial.

6

Single- and multiple-dose administration of caspofungin in patients with hepatic insufficiency: implications for safety and dosing recommendations.

Mistry GC, Migoya E, Deutsch PJ, Winchell G, Hesney M, Li S, Bi S, Dilzer S, Lasseter KC, Stone JA. Mistry GC, et al. Among authors: stone ja. J Clin Pharmacol. 2007 Aug;47(8):951-61. doi: 10.1177/0091270007303764. J Clin Pharmacol. 2007. PMID: 17660480 Clinical Trial.

7

Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects.

Iwamoto M, Wenning LA, Petry AS, Laethem M, De Smet M, Kost JT, Merschman SA, Strohmaier KM, Ramael S, Lasseter KC, Stone JA, Gottesdiener KM, Wagner JA. Iwamoto M, et al. Among authors: stone ja. Clin Pharmacol Ther. 2008 Feb;83(2):293-9. doi: 10.1038/sj.clpt.6100281. Epub 2007 Aug 22. Clin Pharmacol Ther. 2008. PMID: 17713476 Clinical Trial.

8

Lack of a pharmacokinetic effect of raltegravir on midazolam: in vitro/in vivo correlation.

Iwamoto M, Kassahun K, Troyer MD, Hanley WD, Lu P, Rhoton A, Petry AS, Ghosh K, Mangin E, DeNoia EP, Wenning LA, Stone JA, Gottesdiener KM, Wagner JA. Iwamoto M, et al. J Clin Pharmacol. 2008 Feb;48(2):209-14. doi: 10.1177/0091270007310382. Epub 2007 Dec 12. J Clin Pharmacol. 2008. PMID: 18077730 Clinical Trial.

9

Safety, tolerability, pharmacokinetics, and pharmacodynamic properties of taranabant, a novel selective cannabinoid-1 receptor inverse agonist, for the treatment of obesity: results from a double-blind, placebo-controlled, single oral dose study in healthy volunteers.

Addy C, Li S, Agrawal N, Stone J, Majumdar A, Zhong L, Li H, Yuan J, Maes A, Rothenberg P, Cote J, Rosko K, Cummings C, Warrington S, Boyce M, Gottesdiener K, Stoch A, Wagner J. Addy C, et al. Among authors: stone j. J Clin Pharmacol. 2008 Apr;48(4):418-27. doi: 10.1177/0091270008314467. Epub 2008 Feb 7. J Clin Pharmacol. 2008. PMID: 18258750 Clinical Trial.

10

Raltegravir thorough QT/QTc study: a single supratherapeutic dose of raltegravir does not prolong the QTcF interval.

Iwamoto M, Kost JT, Mistry GC, Wenning LA, Breidinger SA, Marbury TC, Stone JA, Gottesdiener KM, Bloomfield DM, Wagner JA. Iwamoto M, et al. Among authors: stone ja. J Clin Pharmacol. 2008 Jun;48(6):726-33. doi: 10.1177/0091270008318007. Epub 2008 Apr 25. J Clin Pharmacol. 2008. PMID: 18441333 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

4,322 results

Search Page